Healthcare

InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference

MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14th at 2:30 pm Eastern Time (ET). A live audio webcast and an archive of the recording will be available through the investors page of InspireMD’s corporate website at https://investors

Inspiremd Inc.September 3, 20261 min read
InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference

About this update from Inspiremd Inc.

MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14th at 2:30 pm Eastern Time (ET). A live audio webcast and an archive of the recording will be available through the investors page of InspireMD's corporate website at  https://investors.inspiremd.com . To request a meeting or for more details about the conferences, please reach out to your institutional contact. About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD's common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company's website. For more information, please visit www.inspiremd.com. Investor Contacts: Jeff Warren LifeSci Advisors [email protected] [email protected]

View stock analysis, news, and events for Inspiremd Inc.

More from Inspiremd Inc.

All Inspiremd Inc. news →